Breaking News

Tweet TWEET

Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results

    Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited
                              Financial Results

PR Newswire

BEIJING, May 17, 2013

BEIJING, May 17, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a
leading provider of vaccines in China, today announced that it will release
its unaudited financial results for the first quarter ended March 31, 2013,
before market on Tuesday, May 28, 2013. The Company will host a conference
call on Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m.
China Standard Time) to review the Company's financial results and provide an
update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or
1-201-689-8471 (International). A replay of the call will be available from 11
a.m. EDT on May 28, 2013, to June 11, 2013, at midnight. To access the
replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and
reference the replay pin number 414862.

A live audio webcast of the call will also be available from the investors
section on the corporate web site at www.sinovac.com. A webcast replay can be
accessed on the corporate website beginning May 28, 2013, and the replay will
remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease). In 2009, Sinovac was the first company
worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and
has manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program.
Sinovac is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Contact:

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910
Email:ir@sinovac.com

Investors
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email:scarrington@theruthgroup.com

Media
Victoria Aguiar
The Ruth Group
Tel: +1-646-536-7013
Email:vaguiar@theruthgroup.com





SOURCE Sinovac Biotech Ltd.

Website: http://www.sinovac.com
 
Press spacebar to pause and continue. Press esc to stop.